-
 PDF
POSTER
Response to Lopinavir/ritonavir-Based HAART and
Its Dependence on Prior ARV Experience:
24-Week Interim Analysis (VIHvir+ Study)
A Burgos, E Cabrero, and the VIHvir+ Study Group
-
PDF
POSTER
Antiretroviral
Therapy in Special Populations: Response to Lopinavir/ritonavir, Tenofovir
DF, and
Emtricitabine in Antiretroviral-Naïve Patients by Gender, Race/Ethnicity,
and Hepatitis Co-infection Status
P Easterbrook, S Green, A Wilkin, et al
-
PDF
POSTER
Lopinavir/ritonavir (LPV/r)-Based Therapy in
Antiretroviral (ARV)-Naïve, HIV-Infected Patients: 6-Year
Follow-up of Study 720
RM Gulick, B da Silva, F McMillan, et
al
-
PDF
POSTER
Prevalence of Multiple Protease Mutations at
Positions 33, 82, 84 and 90 Among PI-Experienced Patients
and the Effecton Virologic Response to Lopinavir/ritonavir-Based Regimens
M King, M Norton, S Brun, et al
-
PDF
POSTER
Efficacy and Tolerance of Lopinavir/ritonavir in Clinical Practice: An
Observational Prospective Cohort of
1278 Patients
A Lafeuillade, M Dupon, J-M Livrozet, et al
-
PDF
POSTER
Adherence in Combination with Lopinavir Inhibitory Quotient (IQ) and
Number of Active Antiretrovirals (ARVs)
Predicts Virologic Response in Highly ARV-Experienced Patients Receiving
High-Dose Lopinavir/ritonavir (LPV/r)
R Bertz, J-L, R. Rode, et al\
-
PDF
POSTER
Lack of Effect of Gastric Acid
Reducing Agents on Lopinavir/ritonavir Plasma Concentrations
in HIV-Infected Patients
R Bertz, Y-L Chiu, C Naylor; et al
-
PDF
POSTER
Immunologic, Virologic and Metabolic Data from the CLARE (CORE Center
Lopinavir/r (LPV/r)
Antiretroviral Effectiveness) Cohort
Adeyemi OM, Simeone E, Shott S, et al
-
PDF
POSTER
Phase 3
Comparison of Lopinavir/ritonavir vs. Investigator-Selected Protease
Inhibitors in Single
PI-Experienced, NNRTI-Naive Patients: 48-Week Results of Study M98-888
RB Pollard, M Thompson, C Hicks, et al
|
